Angioedema and acute urticaria in a patient with COVID 19 pneumonia: Favipiravir side effect or COVID-19 cutaneous manifestation
Öz
Coronavirus disease 2019 (COVID-19) has caused thousands of deaths since it was declared as a pandemic and continues to be one of the most followed topics in the world in terms of its course and treatment. Favipiravir is a broad-spectrum anti-viral agent that has been shown to be effective against various Coronaviruses in vitro. However, as with any drug use, side effects may develop with the use of favipravir treatment. We aimed to present a case of angioedema and acute urticaria whom had COVID 19 pneumonia, that we cannot distinguish as a rare side effect due to favipiravir treatment or COVID-19 cutaneous manifestation. According to the available literature, this is the first case reported in our country.
Anahtar Kelimeler
COVID-19 Favipiravir side effect SARS-CoV-2 Cutaneous manifestations angioedema acute urticaria
Proje Numarası
yok
Kaynakça
- 1. Khambholja K, Asudani D. Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence. Travel Med Infect Dis. 2020;35:101710. doi: 10.1016/j.tmaid.2020.101710.
- 2. Wang M, Cao R, zhang L et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269-71.
- 3. McCreary EK, pogue M, on behalf of the Society of Infectious Diseases pharmacists. COVID-19 Treatment: a review of early and emerging options. OFID . 2020;7:ofaa105.
- 4. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing). 2020. doi: 10.1016/j. eng.2020.03.007
- 5. Galván Casas C, Català A, Carretero Hernández G, Rodríguez-Jiménez P, Fernández-Nieto D, Rodríguez-Villa Lario A, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183(1):71-77. doi: 10.1111/bjd.19163.
- 6. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020;34(5):e212-e213. doi: 10.1111/jdv.16387. PMID: 32215952.
- 7. Marzano AV, Genovese G, Fabbrocini G, et al. Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients. J Am Acad Dermatol 2020;83(1):280-5. doi: 10.1016/j.jaad.2020.04.044.
- 8. Jindal R, Chauhan P. Cutaneous manifestations of coronavirus disease 2019 in 458 confirmed cases: A systematic review. J Family Med Prim Care. 2020;9(9):4563-9. doi: 10.4103/jfmpc.jfmpc_872_20.
- 9. DiFrancesco MF, Solomon SD, Vaduganathan M. Angioedema in COVID 19. Eur Heart J. 2020;34: 3283–4. doi.org/10.1093/eurheartj/ehaa452
- 10. Rahimi H, Tehranchinia Z. A Comprehensive Review of Cutaneous Manifestations Associated with COVID-19. Biomed Res Int. 2020;2020:1236520. doi: 10.1155/2020/1236520.
- 11. Hassan K. Urticaria and angioedema as a prodromal cutaneous manifestation of SARS-CoV-2 (COVID-19) infection. BMJ Case Rep. 2020;13(7):e236981. doi: 10.1136/bcr-2020-236981.
- 12. Abasaeed Elhag SA, Ibrahim H, Abdelhadi S. Angioedema and urticaria in a COVID-19 patient: A case report and review of the literature. JAAD Case Rep. 2020;6(10):1091-1094. doi: 10.1016/j.jdcr.2020.07.042.
- 13. Adeliño R, Andrés-Cordón JF, Aracelis De La Cruz Martínez C. Acute urticaria with angioedema in the setting of coronavirus disease 2019. J Allergy Clin Immunol Pract. 2020;8(7):2386-2387. doi: 10.1016/j.jaip.2020.04.061.
- 14. Najafzadeh M, Shahzad F, Ghaderi N, Ansari K, Jacob B, Wright A. Urticaria (angioedema) and COVID-19 infection. J Eur Acad Dermatol Venereol. 2020;34(10):e568-e570. doi: 10.1111/jdv.16721.
- 15. Cohen AJ, DiFrancesco MF, Solomon SD, Vaduganathan M. Angioedema in COVID-19. Eur Heart J. 2020;41(34):3283-3284. doi: 10.1093/eurheartj/ehaa452.
- 16. Grewal E, Sutarjono B, Mohammed I. Angioedema, ACE inhibitor and COVID-19. BMJ Case Rep. 2020;13(9):e237888. doi: 10.1136/bcr-2020-237888.
- 17. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020;34:e212–e213
Öz
Destekleyen Kurum
yok
Proje Numarası
yok
Kaynakça
- 1. Khambholja K, Asudani D. Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence. Travel Med Infect Dis. 2020;35:101710. doi: 10.1016/j.tmaid.2020.101710.
- 2. Wang M, Cao R, zhang L et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269-71.
- 3. McCreary EK, pogue M, on behalf of the Society of Infectious Diseases pharmacists. COVID-19 Treatment: a review of early and emerging options. OFID . 2020;7:ofaa105.
- 4. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing). 2020. doi: 10.1016/j. eng.2020.03.007
- 5. Galván Casas C, Català A, Carretero Hernández G, Rodríguez-Jiménez P, Fernández-Nieto D, Rodríguez-Villa Lario A, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183(1):71-77. doi: 10.1111/bjd.19163.
- 6. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020;34(5):e212-e213. doi: 10.1111/jdv.16387. PMID: 32215952.
- 7. Marzano AV, Genovese G, Fabbrocini G, et al. Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients. J Am Acad Dermatol 2020;83(1):280-5. doi: 10.1016/j.jaad.2020.04.044.
- 8. Jindal R, Chauhan P. Cutaneous manifestations of coronavirus disease 2019 in 458 confirmed cases: A systematic review. J Family Med Prim Care. 2020;9(9):4563-9. doi: 10.4103/jfmpc.jfmpc_872_20.
- 9. DiFrancesco MF, Solomon SD, Vaduganathan M. Angioedema in COVID 19. Eur Heart J. 2020;34: 3283–4. doi.org/10.1093/eurheartj/ehaa452
- 10. Rahimi H, Tehranchinia Z. A Comprehensive Review of Cutaneous Manifestations Associated with COVID-19. Biomed Res Int. 2020;2020:1236520. doi: 10.1155/2020/1236520.
- 11. Hassan K. Urticaria and angioedema as a prodromal cutaneous manifestation of SARS-CoV-2 (COVID-19) infection. BMJ Case Rep. 2020;13(7):e236981. doi: 10.1136/bcr-2020-236981.
- 12. Abasaeed Elhag SA, Ibrahim H, Abdelhadi S. Angioedema and urticaria in a COVID-19 patient: A case report and review of the literature. JAAD Case Rep. 2020;6(10):1091-1094. doi: 10.1016/j.jdcr.2020.07.042.
- 13. Adeliño R, Andrés-Cordón JF, Aracelis De La Cruz Martínez C. Acute urticaria with angioedema in the setting of coronavirus disease 2019. J Allergy Clin Immunol Pract. 2020;8(7):2386-2387. doi: 10.1016/j.jaip.2020.04.061.
- 14. Najafzadeh M, Shahzad F, Ghaderi N, Ansari K, Jacob B, Wright A. Urticaria (angioedema) and COVID-19 infection. J Eur Acad Dermatol Venereol. 2020;34(10):e568-e570. doi: 10.1111/jdv.16721.
- 15. Cohen AJ, DiFrancesco MF, Solomon SD, Vaduganathan M. Angioedema in COVID-19. Eur Heart J. 2020;41(34):3283-3284. doi: 10.1093/eurheartj/ehaa452.
- 16. Grewal E, Sutarjono B, Mohammed I. Angioedema, ACE inhibitor and COVID-19. BMJ Case Rep. 2020;13(9):e237888. doi: 10.1136/bcr-2020-237888.
- 17. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020;34:e212–e213
Ayrıntılar
| Birincil Dil | İngilizce |
|---|---|
| Konular | Klinik Tıp Bilimleri |
| Bölüm | Olgu Sunumu |
| Yazarlar | |
| Proje Numarası | yok |
| Gönderilme Tarihi | 31 Aralık 2020 |
| Yayımlanma Tarihi | 11 Haziran 2021 |
| Yayımlandığı Sayı | Yıl 2021 Cilt: 12 Sayı: 2 |